UNI-BIO GROUP (00690) has reached a strategic cooperation agreement with the National Engineering Research Center of Wenzhou Medical University and the People's Government of Ouhai District, Wenzhou City.

UNI-BIO GROUP (00690) announced that recently, in Wenzhou City, Zhejiang Province, the group has officially signed a strategic cooperation agreement with Wenzhou Medical University National Engineering Research Center for Growth Factors Drugs and Protein Products (Wenzhou Medical University National Engineering Research Center) and the People's Government of Ou Hai District, Wenzhou City. Discussions were held on the establishment of the "Health Alliance - Wenzhou Medical University Translational Medicine Joint Innovation Laboratory" (Joint Laboratory). This cooperation will strengthen the group's research and development pipeline layout in the fields of skin, ophthalmology, and metabolic-related diseases, and accelerate the implementation of its strategies. According to the agreement, the three parties will leverage their respective advantages in scientific research, industry, and policy to carry out collaborative cooperation throughout the entire chain from basic research, clinical translation to industrialization landing, focusing on the application of growth factor drugs in the field of regenerative medicine. The three parties plan to explore in depth the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, promoting tissue repair, and developing new compound formulations and dosing systems for diseases such as non-alcoholic steatohepatitis (NASH), respiratory system diseases represented by asthma, and bone tissue repair. The global patient population for these diseases is significant, but there is a significant unmet demand for innovative therapies. Through this cooperation and the establishment of the Joint Laboratory in the future, it is expected to fill the treatment gaps in multiple specific indications, further unlocking the clinical and commercial value in the vast chronic disease market. It is reported that Wenzhou Medical University National Engineering Research Center is an independent legal entity hosted by Wenzhou Medical University based on the national research platform "National Engineering Research Center for Growth Factors Drugs and Protein Products." It is led by Academician Li Xiaokun of the Chinese Academy of Engineering and has long been committed to basic research and new drug development in the field of growth factor drugs, leading globally. The People's Government of Ou Hai District, Wenzhou City, is an important promoter and supporter of this strategic cooperation, dedicated to creating a first-class biopharmaceutical industry ecosystem. Its core industrial platform, "China Gene Medicine Valley," provides comprehensive space support and special policy support for the cooperation project from research and development, pilot testing to industrialization. This cooperation is expected to enhance the group's research and development efficiency and success rate in the field of biological innovative drugs, shorten the product development cycle, and enhance its comprehensive competitiveness in the EGF/FGF sub-race. Moreover, the cooperation will also help to promote the application expansion of the group's existing products (including JinYinPeptides, JinYinComfort, etc.) in more clinical scenarios. In addition, the Board believes that this cooperation is a key measure for the group to deepen the synergy of "government-school-enterprise" and integrate into national-level innovation platforms. It is expected to significantly accelerate the research and development and transformation process of cutting-edge innovation pipelines, further consolidate its long-term competitiveness in the field of regenerative medicine, and bring long-term value to shareholders.